Expanding Later-Line Treatment Options for Multiple Myeloma: Paul G. Richardson, MD

Earlier this month, ​the FDA approved isatuximab-irfc (Sarclisa​®​, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two prior lines of treatment, including lenalidomide and a proteasome inhibitor. In this interview with i3 Health, Paul G. Richardson, MD, who served as the co-primary investigator of the ICARIA-MM study, on which the isatuximab approval was based, shares his thoughts on the si...
Continue reading

Isatuximab Approved for Relapsed/Refractory Multiple Myeloma

​The FDA has now approved isatuximab-irfc (Sarclisa®, Sanofi), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least two prior lines of treatment, including lenalidomide and a proteasome inhibitor."While there is no cure for multiple myeloma, [isatuximab] is now another CD38-directed treatment option added to the list of FDA-approved treatments of patients with multiple myeloma who have progressive disease...
Continue reading

Idelalisib: Worse Outcomes in the Clinical Setting vs Clinical Trials

Idelalisib is used as monotherapy to treat relapsed follicular lymphoma (FL) and in conjunction with rituximab for relapsed chronic lymphocytic leukemia (CLL). There is a dearth of data on real-world population outcomes of this therapy. Researchers set out to discover how treatment outcomes of idelalisib for relapsed follicular lymphoma and chronic lymphocytic leukemia in the clinical setting compare with outcomes in clinical trials and found that in the clinical setting, there were less favorab...
Continue reading

Ibrutinib Plus R-CHOP for Non-Germinal Center DLBCL With Wyndham Wilson, MD

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has a 5-year survival rate of 63%. However, patients with non-germinal center B-cell-like (non-GCB) disease and high MYC and BCL2 expression face a poorer prognosis, with limited treatment options. In the phase 3 PHOENIX trial, Wyndham Wilson, MD, the Head of the Lymphoma Therapeutics Section at the National Cancer Institute, and colleagues investigated a combination of ibrutinib and rituximab, cyclophosphami...
Continue reading

Fedratinib for Improved Quality of Life in Myelofibrosis With Ruben Mesa, MD

Patients with myelofibrosis can experience debilitating symptoms that negatively impact their quality of life. In the phase 3 JAKARTA trial, a team of researchers led by Ruben Mesa, MD, the Director of MD Anderson Cancer Center at the University of Texas, San Antonio, found that fedratinib, an oral JAK2 inhibitor, decreased symptom severity and markedly improved quality of life in patients with intermediate- or high-risk primary or secondary myelofibrosis. Dr. Mesa presented the results of the t...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.